Share on StockTwits

Dyax Corp. (NASDAQ:DYAX) Director Thomas L. Kempner unloaded 33,190 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $9.25, for a total transaction of $307,007.50. Following the completion of the sale, the director now directly owns 27,311 shares of the company’s stock, valued at approximately $252,627. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Leerink Swann raised their price target on shares of Dyax Corp. from $7.00 to $8.00 in a research note on Wednesday, July 30th. Separately, analysts at Bank of America reiterated a “positive” rating on shares of Dyax Corp. in a research note on Wednesday, May 28th. Finally, analysts at Bank of America reiterated a “buy” rating on shares of Dyax Corp. in a research note on Saturday, May 17th. They now have a $9.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $12.14.

Shares of Dyax Corp. (NASDAQ:DYAX) traded up 1.19% on Monday, hitting $9.34. 542,644 shares of the company’s stock traded hands. Dyax Corp. has a 52 week low of $4.00 and a 52 week high of $10.99. The stock has a 50-day moving average of $9. and a 200-day moving average of $8.46. The company’s market cap is $1.272 billion.

Dyax Corp. (NASDAQ:DYAX) last released its earnings data on Tuesday, July 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. The company had revenue of $19.59 million for the quarter, compared to the consensus estimate of $14.13 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The company’s revenue for the quarter was up 72.9% on a year-over-year basis. Analysts expect that Dyax Corp. will post $-0.19 EPS for the current fiscal year.

Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.